SG11202000312UA - Encapsulated polynucleotides and methods of use - Google Patents

Encapsulated polynucleotides and methods of use

Info

Publication number
SG11202000312UA
SG11202000312UA SG11202000312UA SG11202000312UA SG11202000312UA SG 11202000312U A SG11202000312U A SG 11202000312UA SG 11202000312U A SG11202000312U A SG 11202000312UA SG 11202000312U A SG11202000312U A SG 11202000312UA SG 11202000312U A SG11202000312U A SG 11202000312UA
Authority
SG
Singapore
Prior art keywords
international
suite
polynucleotides
oncorus
massachusetts
Prior art date
Application number
SG11202000312UA
Inventor
Mitchell H Finer
Edward Kennedy
Lorena Lerner
Original Assignee
Oncorus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncorus Inc filed Critical Oncorus Inc
Publication of SG11202000312UA publication Critical patent/SG11202000312UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

RMACapsid f;yrometry , ,t433e Payx.c .frn; .. BO ---240 16-20 2:2-27 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) HIE Ho IIIII liolomo oimIE (19) World Intellectual Property Organization International Bureau (10) International Publication Number WO 2019/014623 Al (43) International Publication Date 17 January 2019 (17.01.2019) WIPO I PCT Hampshire Street, Suite 401, Cambridge, Massachusetts 02139 (US). LERNER, Lorena; c/o Oncorus, Inc., 50 Hampshire Street, Suite 401, Cambridge, Massachusetts 02139 (US). (74) Agent: WHITTLE, James R. et al.; Cooley LLP, 1299 Pennsylvania Avenue, N.W., Suite 700, Washington, Dis- trict of Columbia 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (51) International Patent Classification: C12N 15/86 (2006.01) Cl 2N 9/12 (2006.01) C12N 15/85 (2006.01) Cl 2N 15/113 (2010.01) C12N 15/63 (2006.01) (21) International Application Number: PCT/US2018/042136 (22) International Filing Date: 13 July 2018 (13.07.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/532,886 14 July 2017 (14.07.2017) US 62/648,651 27 March 2018 (27.03.2018) US (71) Applicant: ONCORUS, INC. [US/US]; 50 Hampshire Street, Suite 401, Cambridge, Massachusetts 02139 (US). (72) Inventors: FINER, Mitchell H.; c/o Oncorus, Inc., 50 Hampshire Street, Suite 401, Cambridge, Massachusetts 02139 (US). KENNEDY, Edward; c/o Oncorus, Inc., 50 (54) Title: ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE Fig. 1 (57) : The present disclosure relates to polynucleotides comprising a nucleic acid sequence encoding a replication competent viral genome, wherein the polynucleotide is capable of producing a replication competent virus when introduced into a cell by a non-viral delivery vehicle. The present disclosure further relates to the encapsulation of the polynucleotides and the use of the polynucleotides and/or particles for the treatment and prevention of cancer. [Continued on next page] WO 2019/014623 Al 1110111111111111Hillinit111111111111111111filliIHIMMINIIIIIIIIIII GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11202000312UA 2017-07-14 2018-07-13 Encapsulated polynucleotides and methods of use SG11202000312UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762532886P 2017-07-14 2017-07-14
US201862648651P 2018-03-27 2018-03-27
PCT/US2018/042136 WO2019014623A1 (en) 2017-07-14 2018-07-13 Encapsulated polynucleotides and methods of use

Publications (1)

Publication Number Publication Date
SG11202000312UA true SG11202000312UA (en) 2020-02-27

Family

ID=65002120

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000312UA SG11202000312UA (en) 2017-07-14 2018-07-13 Encapsulated polynucleotides and methods of use

Country Status (13)

Country Link
US (1) US20200224220A1 (en)
EP (1) EP3652325A4 (en)
JP (2) JP2020530778A (en)
KR (1) KR20200036873A (en)
CN (1) CN111212914A (en)
AU (1) AU2018301701A1 (en)
BR (1) BR112020000839A2 (en)
CA (1) CA3069821A1 (en)
IL (1) IL271969A (en)
MX (1) MX2020000495A (en)
RU (1) RU2020106730A (en)
SG (1) SG11202000312UA (en)
WO (1) WO2019014623A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3070299A1 (en) 2017-07-26 2019-01-31 Oncorus, Inc. Oncolytic viral vectors and uses thereof
MX2020007010A (en) 2018-01-05 2020-12-10 Ottawa Hospital Res Inst Modified orthopoxvirus vectors.
WO2019178098A1 (en) * 2018-03-12 2019-09-19 Mayo Foundation For Medical Education And Research Using infectious nucleic acid to treat cancer
PL3864163T3 (en) 2018-10-09 2024-05-20 The University Of British Columbia Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
US20210403950A1 (en) * 2018-11-13 2021-12-30 Oncorus, Inc. Encapsulated polynucleotides and methods of use
US20220117902A1 (en) * 2019-01-04 2022-04-21 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use
JP2022526094A (en) * 2019-03-14 2022-05-23 マサチューセッツ インスティテュート オブ テクノロジー Manipulated herpes simplex virus-1 (HSV-1) vector and its use
EP4009996A4 (en) * 2019-08-05 2023-09-27 Virogin Biotech Canada Ltd Genetically modified enterovirus vectors
CN114765990A (en) * 2019-10-10 2022-07-19 昂克诺斯公司 Dual viruses and dual oncolytic viruses and methods of treatment
CN113368261A (en) * 2021-06-17 2021-09-10 苏州大学 Non-viral vector and preparation method and application thereof
WO2023225371A1 (en) * 2022-05-20 2023-11-23 Virogin Biotech Canada Ltd Genetically modified enterovirus vectors with enhanced genomic stability
CN115381849A (en) * 2022-06-27 2022-11-25 浙江大学 Active component of anti-oral tumor medicine and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526834A1 (en) * 2003-05-28 2005-03-31 Wisconsin Alumni Research Foundation Recombinant influenza vectors with a polii promoter and ribozymes
JP2007506434A (en) * 2003-09-26 2007-03-22 ノバルティス アクチエンゲゼルシャフト SenecaValley virus-based compositions and methods of treating diseases
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
GB0810912D0 (en) * 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
NZ592070A (en) * 2008-09-26 2012-07-27 Tocagen Inc Gene therapy vectors and humanized yeast cytosine deaminase triple mutant
JP6025567B2 (en) * 2009-12-16 2016-11-16 カッパーアールエヌエー，インコーポレイテッド Treatment of MBTPS1-related diseases by inhibition of the natural antisense transcript against the membrane-bound transcription factor peptidase, site 1 (MBTPS1)
WO2013083753A2 (en) * 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
CN104271749A (en) * 2012-04-18 2015-01-07 雷蒙特亚特特拉维夫大学有限公司 Lipidated glycosaminoglycan particles for the delivery of nucleic acids
JP6396891B2 (en) * 2013-04-17 2018-09-26 新日本製薬株式会社 Genetically modified Coxsackie virus
US10513711B2 (en) * 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
EP3307308A2 (en) * 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
IL298752A (en) * 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Seneca valley virus (SVV) cellular receptor targeted oncotherapy

Also Published As

Publication number Publication date
MX2020000495A (en) 2020-08-20
EP3652325A4 (en) 2021-09-15
JP2020530778A (en) 2020-10-29
BR112020000839A2 (en) 2020-07-21
WO2019014623A1 (en) 2019-01-17
CN111212914A (en) 2020-05-29
KR20200036873A (en) 2020-04-07
IL271969A (en) 2020-02-27
US20200224220A1 (en) 2020-07-16
EP3652325A1 (en) 2020-05-20
RU2020106730A (en) 2021-08-16
JP2023165916A (en) 2023-11-17
AU2018301701A1 (en) 2020-02-27
CA3069821A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
SG11202000312UA (en) Encapsulated polynucleotides and methods of use
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11202000274RA (en) Oligonucleotide compositions and methods thereof
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201807912SA (en) Vaccine against rsv
SG11201909949XA (en) Targeted immunotolerance
SG11201805835WA (en) Modified oncolytic virus
SG11201906147VA (en) Optimized strategy for exon skipping modifications using crispr/cas9 with triple guide sequences
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201811600PA (en) Pseudotyped oncolytic viral delivery of therapeutic polypeptides
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201805805VA (en) Recombinogenic nucleic acid strands in situ
SG11201907561PA (en) Anti-lag-3 antibodies and uses thereof
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201809751XA (en) Egfr inhibitor compounds
SG11201901494UA (en) Acid-alpha glucosidase variants and uses thereof
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201805001UA (en) Method of treating influenza a
SG11201810525XA (en) Anti-gitr antibodies and uses thereof